Ascertaining the Utility of the Glycemia Risk Index for Glucose Outcomes With Hybrid Closed-Loop Therapy in Adolescents and Adults With Type 1 Diabetes.

Autor: Thivolet C; Center for Diabetes DIAB-eCARE, Hospices Civils de Lyon, Lyon, France., Lebbar M; Center for Diabetes DIAB-eCARE, Hospices Civils de Lyon, Lyon, France., Perge K; Department of Paediatric Endocrinology and Diabetes, Hospices Civils de Lyon, Bron, France., Nicolino M; Center for Diabetes DIAB-eCARE, Hospices Civils de Lyon, Lyon, France.; Department of Paediatric Endocrinology and Diabetes, Hospices Civils de Lyon, Bron, France., Villar-Fimbel S; Center for Diabetes DIAB-eCARE, Hospices Civils de Lyon, Lyon, France.
Jazyk: angličtina
Zdroj: Journal of diabetes science and technology [J Diabetes Sci Technol] 2024 Sep; Vol. 18 (5), pp. 1251-1252. Date of Electronic Publication: 2024 Jul 30.
DOI: 10.1177/19322968241258742
Abstrakt: Competing Interests: Declaration of Conflicting InterestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: CT reports personal fees from Abbott Diabetes Care, Glooko, Lilly, Novo-Nordisk, Medtronic, and Sanofi and is an advisory board member for Insulet and Medtronic. SV-F reports personal fees from Abbott Diabetes Care, Lilly, Novo-Nordisk, Medtronic, Roche Diabetes Care, and Sanofi. ML and KP have no conflicts of interest. MN has received travel support for meetings, speaker fees and honoraria from Abbott Diabetes Care, Lilly, Novo-Nordisk, Roche Diabetes Care, and Sanofi, and is an advisory board member for Novo-Nordisk.
Databáze: MEDLINE